

Phase III INDEPENDENCE trial: Luspatercept in patients with MF-associated anemia (NCT04717414)

N = 313

Primary endpoint: RBC-TI for ≥12 consecutive weeks starting within the first 24 weeks.

Eligibility: Patients with MF-associated anemia who require RBC transfusions and who are receiving concomitant JAKi therapy.

